Preclinical study: after heart attack, a boost in anti-inflammatory cells promoted healing
- Details
- Category: Research
The investigators' findings were published in the peer-reviewed Journal of Clinical Investigation.
Bayer and Puhe BioPharma enter into global license agreement for clinical phase I PRMT5 inhibitor
- Details
- Category: Bayer

Enzyme engineering opens door to novel therapies for Parkinson's, cancers and other hard-to-target protein diseases
- Details
- Category: Research
New tool to boost cancer immunotherapy effects
- Details
- Category: Research
Scientists identify potential new genetic target for sickle cell disease treatment
- Details
- Category: Research
The potential target, the FLT1 gene, contributes to the production of a protein, fetal hemoglobin, whose presence is already known to improve the lifespan of people with sickle cell disease.
AstraZeneca enters license agreement with Alteogen
- Details
- Category: AstraZeneca

Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma
- Details
- Category: Roche

Keeping fit and building muscle could increase survival rates in cancer patients
- Details
- Category: Research
Around 20 million new cancer cases were reported in 2022, with 9.7 million cancer deaths reported world-wide during the same period, with experts expecting the trend to increase in the coming decades.
Continued medication important for heart failure patients
- Details
- Category: Research
"Our finding raises awareness about the importance of implementing and not withdrawing medical treatments in daily clinical practice even if patients with heart failure experience an improvement in symptoms and pump function," says the study's last author Gianluigi Savarese,
Newly identified bacterial protein helps design cancer drug delivery system
- Details
- Category: Research
In a paper published in PNAS, researchers at King's College London and the University of Washington describe the unique 3D structure of this protein, which is now being used to develop cancer drug delivery systems that can target drugs to tumour sites.